You are here

MindBio Therapeutics Corp.

MindBio Therapeutics Corp.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
MBIO
CSE Index: 
Currency: 

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials.  MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing.  MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. The Company has also started dosing in a Phase 2B Depression Trial.   MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

You are here

MindBio Therapeutics Corp. (MBIO)

SEDAR Information

Company Info

Address
1055 West Georgia Street,1500 Royal Centre P.O Box 11117
Vancouver, BC V6E 4N7
Canada
Phone
+61 4331140886
Email
justin@mindbiotherapeutics.com
Website
https://www.mindbiotherapeutics.com
Listing date
Friday, May 5, 2023
Transfer Agent
Odyssey Trust Company

Capitalization

Issued & Outstanding: 
135047305
Reserved for Issuance: 
38669449

Company Officers

Justin Hanka, Chief Executive Officer and Director
Gavin Upiter, Non-Executive Director and Chairman
Dr Zena Burgess, Non Executive Director

Bulletins

04/05/2023

2023-0505 - New Listing - MindBio Therapeutics Corp. (MBIO)

le 4 mai/May 2023

The common shares of MindBio Therapeutics Corp. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.